Keith Flaherty

Keith T.
Flaherty is the founder of X4 Pharmaceuticals, Inc., founded in 2010 and again noted in 2014, with no titles listed.
Dr. Flaherty is the founder of Strata Oncology, Inc., founded in 2015, holding the title of Director since 2015.
Dr. Flaherty was the founder of Scorpion Therapeutics, Inc., founded in 2020, with the title of Director formerly held.
Dr. Flaherty is also the founder of Apricity Health LLC..
Dr. Flaherty currently serves as Deputy Chairman at Biomarker Science Group LLC.
Dr. Flaherty is Director-Clinical Research at The Massachusetts General Hospital since 2009.
Dr. Flaherty is Editor-in-Chief at Clinical Cancer Research.
Dr. Flaherty is President-Elect at the American Association for Cancer Research, starting in 2025.
Dr. Flaherty is Professor at Harvard Medical School since 2009.
Formerly, Dr. Flaherty was Independent Director at Clovis Oncology, Inc. from 2013 to 2023.
Dr. Flaherty was Director at Loxo Oncology, Inc. from 2013 to 2019.
Dr. Flaherty was Independent Director at Checkmate Pharmaceuticals, Inc. from 2019 to 2022.
Dr. Flaherty was Independent Director at Kinnate Biopharma, Inc. from 2019 to 2024.
Education includes undergraduate studies at Yale University and a doctorate from The Johns Hopkins University School of Medicine.